J. Venäläinen

发表

Prolyl Endopeptidase Is Involved in Cellular Signalling in Human Neuroblastoma SH-SY5Y Cells

J. Tenorio-Laranga, K. Puttonen, M. Forsberg, 2011, Neurosignals.

On the role of prolyl oligopeptidase in health and disease

J. A. García-Horsman, J. Venäläinen, P. Männistö, 2007, Neuropeptides.

Characterization of membrane‐bound prolyl endopeptidase from brain

J. Tenorio-Laranga, J. A. García-Horsman, J. Venäläinen, 2008, The FEBS journal.

Gene Expression Profiling of Gliadin Effects on Intestinal Epithelial Cells Suggests Novel Non-Enzymatic Functions of Pepsin and Trypsin

D. Greco, P. Saavalainen, M. Gentile, 2013, PloS one.

Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders.

J. A. García-Horsman, Aaro J. Jalkanen, J. Venäläinen, 2007, Drug news & perspectives.

Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues

T. Myöhänen, M. Piltonen, J. A. García-Horsman, 2008, Histochemistry and Cell Biology.

Enzymatic detoxification of gluten by germinating wheat proteases: Implications for new treatment of celiac disease

K. Kaukinen, M. Mäki, L. Sollid, 2009, Annals of medicine.

4-Phenylbutanoyl-2(S)-acylpyrrolidines and 4-phenylbutanoyl-L-prolyl-2(S)-acylpyrrolidines as prolyl oligopeptidase inhibitors.

Erik A. A. Wallén, J. Gynther, M. Forsberg, 2002, Bioorganic & medicinal chemistry.

Evolutionary relationships of the prolyl oligopeptidase family enzymes.

R. Juvonen, J. Venäläinen, P. Männistö, 2004, European journal of biochemistry.

2(S)-(Cycloalk-1-enecarbonyl)-1-(4-phenyl-butanoyl)pyrrolidines and 2(S)-(aroyl)-1-(4-phenylbutanoyl)pyrrolidines as prolyl oligopeptidase inhibitors.

Erik A. A. Wallén, Sami Poutiainen, M. Forsberg, 2007, Bioorganic & medicinal chemistry.

Conformationally rigid N-acyl-5-alkyl-L-prolyl-pyrrolidines as prolyl oligopeptidase inhibitors.

Erik A. A. Wallén, J. Gynther, M. Forsberg, 2003, Bioorganic & medicinal chemistry.

Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A

K. Kaukinen, I. Korponay-Szabó, M. Mäki, 2011, Clinical and experimental immunology.

Distribution of Immunoreactive Prolyl Oligopeptidase in Human and Rat Brain

R. Miettinen, E. Tupala, T. Myöhänen, 2007, Neurochemical Research.

Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture

K. Kaukinen, M. Mäki, K. Juuti-Uusitalo, 2008, Clinical and experimental immunology.

Degradation of coeliac disease‐inducing rye secalin by germinating cereal enzymes: diminishing toxic effects in intestinal epithelial cells

K. Kaukinen, T. Mauriala, S. Auriola, 2010, Clinical and experimental immunology.

Spatial association of prolyl oligopeptidase, inositol 1,4,5-triphosphate type 1 receptor, substance P and its neurokinin-1 receptor in the rat brain: An immunohistochemical colocalization study

T. Myöhänen, J. Garcia-horsman, J. Venäläinen, 2008, Neuroscience.

Cellular and subcellular distribution of rat brain prolyl oligopeptidase and its association with specific neuronal neurotransmitters

T. Myöhänen, M. Piltonen, J. A. García-Horsman, 2008, The Journal of comparative neurology.

Dicarboxylic acid bis(L-prolyl-pyrrolidine) amides as prolyl oligopeptidase inhibitors.

Erik A. A. Wallén, J. Gynther, M. Forsberg, 2002, Journal of medicinal chemistry.

Deficient activity of mammalian prolyl oligopeptidase on the immunoactive peptide digestion in coeliac disease

K. Kaukinen, I. Korponay-Szabó, M. Mäki, 2007, Scandinavian journal of gastroenterology.

Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors.

Erik A. A. Wallén, J. Gynther, M. Forsberg, 2006, Biochemical pharmacology.

Slow-binding inhibitors of prolyl oligopeptidase with different functional groups at the P1 site.

Erik A. A. Wallén, J. Gynther, R. Juvonen, 2004, The Biochemical journal.

Beneficial effect of prolyl oligopeptidase inhibition on spatial memory in young but not in old scopolamine-treated rats.

Erik A. A. Wallén, K. Puttonen, Anne Mannila, 2006, Basic & clinical pharmacology & toxicology.

Prolamin hydrolysis in wheat sourdoughs with differing proteolytic activities.

T. Sontag-Strohm, H. Salovaara, J. Venäläinen, 2007, Journal of agricultural and food chemistry.

Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819.

A. Poso, Erik A. A. Wallén, J. Gynther, 2002, Biochemical pharmacology.

An introduction of a pyridine group into the structure of prolyl oligopeptidase inhibitors.

Erik A. A. Wallén, M. Forsberg, J. Vepsäläinen, 2006, Bioorganic & medicinal chemistry letters.

Brain prolyl oligopeptidase activity is associated with neuronal damage rather than β-amyloid accumulation

H. Tanila, T. van Groen, I. Alafuzoff, 2001, Neuroreport.

Discovery of sulfonamides and 9-oxo-2,8-diazaspiro[5,5]undecane-2-carboxamides as human kynurenine aminotransferase 2 (KAT2) inhibitors.

M. Augustin, T. Kalliokoski, Marja Rantanen, 2020, Bioorganic & medicinal chemistry letters.

A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors.

Erik A. A. Wallén, J. Gynther, J. Huuskonen, 2004, Journal of medicinal chemistry.

New prolyl oligopeptidase inhibitors developed from dicarboxylic acid bis(l-prolyl-pyrrolidine) amides.

Erik A. A. Wallén, J. Gynther, M. Forsberg, 2003, Journal of medicinal chemistry.